AMGN Dividend data by YCharts
The better dividend stock is...
Even though AbbVie's projected yield of 3.2% looks far juicier than Amgen's 1.9% dividend yield, the truth of the matter is that Amgen is the better dividend stock. Amgen still needs to prove it can actually deliver on some of its late-stage compounds, but at least it's finally hit that point where we could see its organic growth surge. AbbVie's hepatitis C direct-acting antiviral will certain help ebb some of its Humira woes, as will the Shire buy, but I'd consider the company no lock to be able to keep its payout where it is now.
If you want more great dividend ideas look no further than these high-yield picks from our best analysts!
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here .
The article Better Dividend Stock: Amgen, Inc. or AbbVie Inc.? originally appeared on Fool.com.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
